Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies for central nervous system (CNS) disorders. The ... Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies for central nervous system (CNS) disorders. The company focuses on addressing medical conditions with significant unmet needs, offering treatments where existing options are limited or inadequate. Among its key marketed products are Auvelity, an oral medication for major depressive disorder, and Sunosi, for managing excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. Axsome’s pipeline includes investigational therapies aimed at conditions such as Alzheimer’s disease agitation and migraine. By leveraging differentiated drug mechanisms and pursuing regulatory strategies that accelerate development, Axsome plays a crucial role in expanding treatment horizons for patients affected by CNS diseases. The company is noted for its robust intellectual property strategy and a management team with deep expertise in pharmaceutical development, underpinning its impact within the pharmaceuticals sector and its relevance in advancing CNS-focused therapeutic innovation.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Energy Management data not yet covered for Axsome Therapeutics

We have not yet reviewed Axsome Therapeutics's disclosures for Energy Management data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Axsome Therapeutics's data?

Create a free Tracenable account to signal interest in having our team review data for Axsome Therapeutics.

Legal Center Contact Us